Lipocine Inc. — Q2 2017 Form 10-Q
Reporting period: Three and six months ended June 30, 2017; filed August 7, 2017. Lipocine is a clinical-stage pharmaceutical company developing oral therapies for men’s and women’s health. It reported no product revenue and remains dependent on financing and development progress.
Financial results and liquidity
Amounts below are in U.S. dollars; figures are unaudited.
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $4.11 million | $2.57 million | $7.19 million | $5.24 million |
| General and administrative expense | $2.03 million | $3.25 million | $3.86 million | $7.64 million |
| Net loss | $6.09 million | $5.76 million | $10.95 million | $12.77 million |
| Loss per share, basic and diluted | $0.31 | $0.32 | $0.58 | $0.70 |
| Operating cash used | — | $7.84 million | $11.69 million |
- Q2 operating expenses rose 6% year over year as R&D spending increased, principally for LPCN 1021 dosing studies. G&A fell, mainly due to lower pre-commercialization and business-development spending and reduced personnel costs after 2016 restructurings.
- For the first half, lower G&A more than offset higher R&D, reducing net loss by $1.82 million year over year. Q2 net loss increased by $0.33 million. Profit margins are not meaningful because the company had no revenue.
- At June 30, cash and cash equivalents were $16.63 million and marketable securities were $11.19 million, totaling approximately $27.83 million. Current assets were $27.93 million and current liabilities $2.90 million. The company reported no debt or credit facility.
- Six-month financing cash flow was $8.80 million, including $8.41 million net proceeds from ATM share sales and $0.39 million from option exercises. Shares outstanding increased; 20,672,508 common shares were outstanding on August 4, 2017.
Material changes and business developments
- LPCN 1021’s June 2016 FDA Complete Response Letter identified concerns with its dosing algorithm. In June 2017, the company reported that its dosing-validation study met the FDA’s stated primary efficacy thresholds: 80% achieved average testosterone in the normal range, with a 72% lower confidence bound. The dosing-flexibility study reported 70% within range. The company said twice-daily dosing would be the basis for resubmission.
- Management expected to resubmit the LPCN 1021 NDA in August 2017. Approval is not assured; the FDA may request further information, studies, labeling restrictions, or other actions.
- LPCN 1111 remained in Phase 2 development; an FDA End-of-Phase-2 meeting was expected in Q4 2017. LPCN 1107 remained in Phase 2 development; FDA feedback on its proposed Phase 3 protocol was expected in Q3 2017. Manufacturing scale-up and a food-effect study remained ahead of or alongside Phase 3 work for LPCN 1107.
- Clarus announced it had submitted an NDA for competing oral testosterone product Jatenzo in June 2017, and could launch before LPCN 1021 if approved first.
Outlook, risks and contingencies
- Management estimated existing capital would fund projected operating requirements through June 30, 2018, but said the estimate depends on assumptions and additional capital will ultimately be needed. It anticipated approximately $3.5 million in additional LPCN 1021 R&D costs for analysis, NDA resubmission and manufacturing activities.
- The company expects continued operating losses and significant expenses. Delayed or denied FDA approval, further trial requirements, commercialization costs, or limited access to financing could require spending reductions or delay development. Further equity financing could dilute existing shareholders.
- The company reported a pending securities class action alleging misleading statements related to the LPCN 1021 NDA. It filed a motion to dismiss; management said it considered the claims without merit and did not expect a material financial impact, while noting an insurance retention payment would be required. A separate Clarus patent interference remained pending; a related infringement lawsuit had been dismissed, but could be refiled if LPCN 1021 is approved and marketed.
- Other obligations include leases with $252,840 in minimum payments at June 30, 2017, and a perpetual 1% royalty to Abbott on LPCN 1021 net sales if launched, subject to stated initial caps and generic-product reduction terms. No litigation contingency was accrued because management did not consider any matter probable and estimable.
- Disclosure controls were assessed as effective at June 30, 2017. The filing reported no material change in internal control over financial reporting and no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether and when the FDA accepts and acts on the LPCN 1021 NDA resubmission, and whether it requires additional trials, warnings, or restrictions.
- Full clinical data, safety findings, and FDA interpretation of the DV and DF studies, including the reported Cmax results.
- Cash burn, remaining ATM capacity, financing needs, and the assumptions underlying management’s runway estimate through June 30, 2018.
- FDA feedback and development costs for LPCN 1111 and LPCN 1107, including Phase 3 design, enrollment and manufacturing requirements.
- Status and potential cost of the securities litigation and patent proceedings, as well as competitive timing for Jatenzo.